Kedrion Biopharma Launches QIVIGY® National Distribution Network for Better Patient Access

Kedrion Biopharma Expands Access to QIVIGY

Kedrion Biopharma has officially launched a national distribution network for QIVIGY, its innovative 10% intravenous immunoglobulin (IVIG) therapy, approved by the U.S. Food and Drug Administration (FDA) in late 2025. This new initiative facilitates extensive access to QIVIGY, making it available in specialty pharmacies, infusion centers, hospitals, and other healthcare services nationwide. The establishment of this distribution model underscores Kedrion's commitment to enhancing patient care by ensuring that healthcare providers can reliably obtain this essential treatment.

Key Aspects of QIVIGY's Launch

The comprehensive distribution network includes partnerships with established specialty distributors such as CuraScript SD, Cencora, Inc., Cardinal Health, McKesson Plasma and Biologics, and BioCare, Inc. These collaborations are crucial for providing a robust supply chain and efficient ordering systems. Additionally, Kedrion’s relationships with key group purchasing organizations (GPOs) like Premier, Inc. and Innovatix are designed to improve the onboarding process for healthcare entities engaging with QIVIGY. This means that patients will benefit from streamlined access to the product as demand for IVIG therapies increases.

Kedrion's Chief Executive Officer, Ugo Di Francesco, emphasized the significance of QIVIGY's introduction in the U.S. market. "This rollout signifies our continuous advancement as a fully integrated biopharmaceutical entity," he stated. The product represents the culmination of years of investment in scientific research and development, proving Kedrion's capability to produce a consistent, high-quality IVIG therapy globally.

The Importance of QIVIGY

QIVIGY is particularly geared towards adults suffering from primary humoral immunodeficiency, a condition that stems from the body's incapability to produce adequate immunoglobulin levels. Its efficacy and reliability are underscored by Kedrion's integrated global manufacturing framework, which ensures long-term consistency in product quality and supply. The objective is clear: to expand access to high-quality plasma-derived therapies and to uphold stringent quality standards across its products.

Bob Rossilli, Kedrion’s Chief Commercial Officer, articulated the company’s vision moving forward, stating that QIVIGY's accessibility is a crucial moment not just for Kedrion but also for patients reliant on immunoglobulin therapies. This launch reinforces the company’s broad immunoglobulin portfolio and assures dependable supply channels designed to enhance healthcare service delivery.

Safety and Usage Considerations

Similar to any medical treatment, QIVIGY comes with important safety considerations. It can lead to complications such as blood clots, renal dysfunction, and hypersensitivity reactions in certain patients. Therefore, strict protocols must be followed when administering QIVIGY, including hydration and monitoring for adverse reactions. This proactive approach is vital in ensuring patient safety while using the therapy.

Looking Ahead

Kedrion Biopharma continues to position itself as a leader in providing vital therapies for immunodeficiencies and other debilitating conditions. Their investment in a national distribution model for QIVIGY marks a significant development in the healthcare landscape, offering hope and enhanced treatment options for patients across the United States. Kedrion is dedicated to forging partnerships within the healthcare community to improve patient outcomes and foster innovation in treatment standards.

In conclusion, Kedrion Biopharma’s launch of QIVIGY through a comprehensive distribution plan exemplifies its dedication to patient care and commitment to the biopharmaceutical industry. As the demand for these essential therapies grows, the company's proactive measures lay a firm groundwork for improved patient access and health outcomes across diverse healthcare settings.